Teijin Pharma, based in Japan, has entered into an exclusive global license agreement with Swiss firm Novartis to research, develop, manufacture and commercialise an investigational preclinical candidate for proteinuric kidney diseases.
Teijin Limited and Axcelead, jointly announced their basic agreement on a capital and business alliance to establish a joint venture company that will primarily utilize the drug discovery research capabilities of Teijin Pharma Limited, the Teijin Group's core healthcare company. Teijin and Axcelead will now determine the name, ownership ratio and other details of the new company, aiming to conclude a final agreement within the fiscal year ending in March 2024 and then establish the company promptly thereafter.
Tokyo, Japan, September 5, 2022 --- Teijin Pharma Limited, the core company of the Teijin Group's healthcare business, announced today that on August 31 the company obtained manufacturing and sales approval from Japan's Ministry of Health, Labour and Welfare for its abaloparatide acetate treatment OSTABALO® Subcutaneous Injection Cart 1.5mg. The newly approved specification, which is for the treatment of osteoporosis, is expected to help promote bone formation in patients with high risk of bone fractures.
PARIS & TOKYO--(BUSINESS WIRE)--Iktos, a company specialized in Artificial Intelligence (AI) for new drug design, and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business that provides comprehensive healthcare services to improve the quality of life, today announced a strategic collaboration agreement in Artificial Intelligence for new drug design.
Merz Therapeutics , a Merz Group company and a leader in neurotoxins, and Teijin Pharma Limited , the core company of Teijin Group 's health operations , today jointly announced that Teijin Pharma has been granted additional approval by the Japanese Ministry of Health, Labor and Welfare (MHLW) to market Xeomin ® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units for the treatment of lower extremity spasticity.
Merz Therapeutics , a Merz group company and leader in neurotoxins, and Teijin Pharma Limited , Teijin group's main company in healthcare, jointly announced today that Teijin Pharma obtained additional approval from the Japanese Ministry of Health, Labor and Welfare for the placing on the market of Xeomin ® (incobotulinumtoxinA) administered by intramuscular injection in boxes of 50, 100 or 200 units for processing spasticity of the lower limbs.
Osaka, Japan, April 1, 2021 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion1.?This asset transfer agreement was announced in February 2021.
Takeda Pharmaceutical has completed the asset transfer linked to a portfolio of select non-core products in Japan to Teijin Pharma for $1.25bn (JPY133bn).
Osaka, Japan, April 1, 2021 --- Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that it has completed the asset transfer associated with a portfolio of select non-core products in Japan to Teijin Pharma Limited (“Teijin Pharma”) for JPY 133.0 billion1.?This asset transfer agreement was announced in February 2021.
TOKYO (Reuters) - Takeda Pharmaceutical Co said on Friday it agreed to sell four diabetes products in Japan to Teijin Pharma Ltd for 133 billion yen ($1.25 billion).